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Abstract
A rapid and accurate assessment of the antitumor
efficacy of new therapeutic drugs could speed up drug
discovery and improve clinical decision making. Based
on the hypothesis that most effective antitumor agents
induce apoptosis, we developed a near-infrared fluo-
rescent (NIRF) annexin V to be used for optical sensing
of tumor environments. To demonstrate probe specif-
icity, we developed both an active (i.e., apoptosis-
recognizing) and an inactive formof annexin Vwith very
similar properties (to account for nonspecific tumor
accumulation), and tested the agents in nudemice each
bearing a cyclophosphamide (CPA) chemosensitive
(LLC) and a chemoresistant LLC (CR-LLC). After
injection with active annexin V, the tumor–annexin V
ratio (TAR; tumor NIRF/background NIRF) for untreated
micewas 1.22F 0.34 for LLC and 1.43F 0.53 for CR-LLC
(n=4). The LLC of CPA-treated mice had significant
elevations of TAR (2.56F 0.29, P= .001, n=4), but only a
moderate increase was obtained for the CR-LLC
(TAR=1.89F 0.19, P= .183). The in vivo measurements
correlated well with terminal deoxyribosyl transferase-
mediated dUTP nick end labeling indexes. When
inactive Cy–annexin V was used, with or without CPA
treatment and in both CCL and CR-CCL tumors, tumor
NIRF values ranged from 0.91 to 1.17 (i.e., tumor were
equal to background). We conclude that active Cy–
annexin V and surface reflectance fluorescence imag-
ing provide a nonradioactive, semiquantitative method
of determining chemosensitivity in LLC xenografts. The
method maybe used to image pharmacologic re-
sponses in other animal models and, potentially, may
permit the clinical imaging of apoptosis with non-
invasive or minimally invasive instrumentation.
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Introduction
A noninvasive method of predicting tumor response early in
the course of a chemotherapeutic regime might find con-
siderable use in animal models assessing drug potency, or
in the treatment of human disease. Imaging extracellular-facing
phosphatidylserine (PS), an early marker of apoptosis, with a
technetium-labeled annexin V (Tc annexin V) has been sug-
gested as a method of monitoring tumor response to chemo-
therapy [8]. As cells proceed along the pathway(s) to apoptosis,
PS, a lipid normally facing the cytoplasm, flips and faces the
extracellular fluid [15]. The protein annexin V binds PS strongly,
specifically in a calcium-dependent fashion, which is a reflec-
tion of its biologic role as an anticoagulant [5,9,11,21,26]. PS is
attractive as a target for imaging the response to chemotherapy
because different forms of chemotherapy have a common
propensity to induce apoptosis [7,12,14,16,24], and PS is a
feature of apoptotic cells regardless of how apoptosis is
induced [26]. Moreover, resistance to chemotherapy may
reflect cellular mechanisms that prevent the chemotherapy
from inducing apoptosis.
An optical method for imaging apoptosis would not only
eliminate patient exposure to radiation and the need for frequent
radiotracer synthesis—it might enable the visualization of apop-
tosis in settings quite different from that required of scintigraphic
imaging. Thesemight include intraoperative visualization, using
surface-weighted surface reflectance imaging equipment
[13,28] or, in a minimally invasive fashion, use of fluorescent
endoscopes [30,31]. We therefore decided to investigate
whether a near-infrared fluorescent (NIRF) form of annexin V
could be developed and used in conjunction with a surface
reflectance fluorescence imaging, to provide a semiquantitative
method of imaging PS exposure in an animal model. Surface
reflectance fluorescence imaging illuminates the animal with
light that excites a fluorochrome, and acquires an image at a
second longer wavelength of emitted light from the animal. We
describe the synthesis of an NIRF conjugate of annexin V and
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its use in imaging PS when a chemosensitive Lewis lung
carcinoma (LLC) and a chemoresistant LLC (CR-LLC) were
treated with cyclophosphamide (CPA). The NIRF conjugate
of annexin V and our imaging technique provided a semi-
quantitative method of determining tumor PS that was
reflected with CPA treatment and tumor chemosensitivity.
Materials and Methods
Labeling of Annexin V with Fluorescent Dyes
Annexin V was obtained from Theseus Imaging, Cam-
bridge,MA andwas identical to that used clinically. Annexin V
migrated as a single band of 36 kDa by SDS-PAGE, confirm-
ing its purity (data not shown). To synthesize a Cy5.5-labeled
annexin V, we added 333 Al of annexin V (3.0 mg/ml dialyzed
against 0.1 M bicarbonate pH, 8.0) to a vial of the Cy5.5 N-
hydroxysuccinimide ester (Amersham-Pharmacia, Piscat-
away, NJ). After 20minutes at room temperature, the mixture
was transferred into a second Cy5.5 vial and incubated for
another 40 minutes at room temperature. Protein was sepa-
rated from unreacted dye by two successive spin separations
using 10 ml of BioGel P6 columns in PBS, pH 7.4 (Bio-Rad,
Hercules, CA). The concentration of coupled Cy5.5 dye was
determined spectrophotometrically (E678 = 250,000 M
1
cm1). Protein was determined by the BCA method (Bio-
Rad, Richmond, CA). The conjugate had 1.1 Cy5.5 attached
per mole of annexin V. To synthesize annexin V–Cy5.5
conjugates with a range of dye-to-protein ratios, a vial of
Cy5.5 was solubilized with 7 Al of DMSOand 1.0, 2.0, or 4.0 Al
added to 30 Ag of annexin V (0.1 M Na–carbonate buffer, pH
8.0) to give a final volume of 20 Al. The reaction tubes were
incubated for 1.5 hours at room temperature. After adding 30
Al of PBS, pH 7.4, the protein was separated from unreacted
dye by two successive spin separations using 1 ml of Biospin
P6 columns equilibrated with PBS, pH 7.4 (Bio-Rad). The
resulting conjugates had 1.6, 2.0, and 2.4 mol of dye mole-
cules per mole of protein. Conjugates are referred to as
Cy5.5n–annexin V, where n is the mole of dye per mole of
protein.
To synthesize a fluorescein-labeled annexin V (FITC–
annexin V), 1 mg of annexin V in 200 Al of the buffer above
was reacted with 200 Ag of fluorescein isothiocyanate (FITC)
in 1 ml of buffer for 1.5 hours at room temperature. The
protein was separated from unreacted dye by dual-spin
separation, as above. The concentration of coupled fluores-
cein was determined spectrophotometrically (E494 = 72000
M 1 cm 1). The conjugate had a ratio of 1.6 dye molecules/
protein. The activity of this FITC–annexin V was similar to
that from a commercial source (Clontech, Palo Alto, CA).
Cell Binding of Fluorescent Annexin V Conjugates
Jurkat T cell cells (Clone E6-1, no. TIB-152; ATCC,
Manassas, VA) were grown in RPMI 1640 medium with
10% fetal bovine serum (Vitacell no. 30-2021; ATCC), which
was changed every 2 or 3 days. Apoptosiswas induced by the
addition of 7 Al of camptothecin (1 mM in DMSO) per milliliter
of culture medium and incubation for 5 to 6 hours at 37jC.
Induction of apoptosis was verified by staining with propidium
iodide and FITC–annexin V using a calcium-containing bind-
ing buffer (1.8 mM CaCl2, 10 mM HEPES, 150 mM NaCl, 5
mMKCl, 1mMMgCl2, pH 7.4). The cells were analyzedwith a
FACS-Calibur cytometer (Becton Dickinson, San Jose, CA)
according to the manufacturer’s manual. Cells were incu-
bated with dye–annexin V conjugates (0.1 Ag of each dye–
annexin V in 200 Al of binding buffer) for 10 minutes at room
temperature. For competition assays, cells were incubated
with a 10-fold protein excess (1.0 Ag of inhibitor dye–annexin
V or annexin V) for 5 minutes before the addition of dye–
annexin V as above. Flow cytometry was as above.
Fluorescence Microscopy
Ten microliters of cell suspension was applied to a micro-
scopy slide, placed on an Axiovert Ziess microscope (Carl
Zeiss MicroImaging, Thornwood, NJ), and photographed by
employing a SenSys CCD camera (Roper Scientific, Tren-
ton, NJ) attached to a G4-PowerMac (Apple Computer,
Cupertino, CA).
Tumor Model
LLC cell lines sensitive to and resistant to CPA were
provided by Dr. Timothy Browder (Children’s Hospital, Bos-
ton, MA) and have been described [3]. CPA-sensitive and
CPA-resistant cell lines are denoted as CLL and CR-CLL,
respectively. Cells were grown as monolayers in DMEM
(Cellgro; Mediatech, Washington, DC), containing 10% inac-
tivated FBS, 1% penicillin/streptomycin, and 0.15% L-gluta-
mineat 37jC inahumidified 5%CO2atmosphere.Onemillion
cells (0.05 ml) were subcutaneously injected in female athy-
mic nu/nu mice (28 g; Jackson Laboratory, Bar Harbor, ME).
Ten and 12 days after tumor injection, the animals received
CPA170mg/kg, i.p. (Mead Johnson, Princeton, NJ). One day
after the second CPA treatment, the animals received 61
nmol/kg Cy5.5 dye, present as either active or inactive Cy–
annexin V, by tail vein injection and were imaged 90 minutes
later. All procedures were approved by theMGHAnimal Care
and Use Committee.
Optical Imaging
The animals were anesthesized with ketamine/xylazine
(200/30 mg/kg, i.p). NIRF and white light images were
acquired using a reflectance fluorescence imaging system
as described [13,28]. To obtain tumor NIRF signals from
tumors, the mean signal intensity was measured with ImageJ
(National Institute of Health, USA) from hand-drawn regions
of interest for each tumor or region adjacent to the tumor.
The tumor mean NIRF signal was then divided by the back-
ground mean NIRF signal to obtain the tumor–annexin V
ratio (TAR). The tumor margins were evident from the
images of the animals, physical examination, and dissection.
Histology
After imaging, the animal was euthanized (pentobarbital,
200 mg/kg, i.p.), and tumors were excised, snap frozen,
and cut into sections. Frozen sections were stained for
apoptosis by a commercially available terminal deoxyribosyl
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transferase-mediated dUTP nick end labeling (TUNEL)
method (ApopTag kit; Intergen, Purchase, NY). Slides were
photographed using an Axiovert Ziess microscope (Carl
Zeiss MicroImaging).
Results
To examine the ability of annexin V to retain its activity after
modification with the dye Cy5.5, we prepared four Cy5.5–
annexin Vs with different numbers of Cy5.5 attached per
mole of protein. We then analyzed the conjugates in a
competition assay using FITC–annexin V binding to PS on
camptothecin-treated Jurkat T cells. The induction of PS
exposure following treatment with camptothecin has been
well studied [23,25]. Cells were incubated with the conjugate
FITC–annexin V and a 10-fold excess of various Cy5.5-
labeled annexin Vs or unlabeled annexin V, and cell-
associated FITC fluorescence (FL1 channel) was obtained
(Figure 1). Values were normalized to the median fluo-
rescence with no added annexin V. The conjugate
Cy5.52.4–annexin V gave a displacement of 0.98 com-
pared to a reference value of 1.0 for no added annexin V,
and is referred to as inactive Cy–annexin V. As the
number of attached Cy5.5 molecules decreased, the
ability of the Cy5.5–annexin Vs to displace FITC–annexin
V increased. The conjugate Cy5.51.1–annexin V gave a
displacement of 0.32, compared to a value of 0.17 for
unlabeled annexin V. The Cy5.51.1–annexin V conjugate
is referred to as ‘‘active Cy–annexin V’’ below. Inactive
Cy–annexin V serves as control material for imaging
studies, with the same fluorochrome and nearly the same
size as active Cy–annexin V, but unable to bind PS.
The ability of active Cy–annexin V to bind cells was
further evaluated as shown in Figure 2. We incubated a
mixture of active Cy5.5–annexin V and FITC–annexin V
with untreated (Figure 2A) and camptothecin-treated cells
(Figure 2B) and submitted them to FACS analysis. Untreated
cells failed to bind either probe (91.8%) or bound both probes
(7.2%; Figure 2A). Treated cells bound both probes (59.1%)
or failed to bind either probe (36.7%; Figure 2B). By FACS
analysis, active Cy5.5–annexin V and FITC–annexin V
bound the same cells after treatment with camptothecin.
Fluorescence micrographs of cells treated with campto-
thecin for 7.5 hours and then stained with active Cy–annexin
V, and a probe for active caspases (FITC-VAD-FMK) are
shown in Figure 2C. As expected, active Cy–annexin V was
membrane-bound (red), whereas FITC-VAD-FMK (green)
gave an intense cytoplasmic stain. These doubly stained
cells comprised 41.0% of cells by FACS analysis. Also
shown are examples of cells that were stained for either
active caspase or with active Cy–annexin V. Caspase/
annexin V+ cells (14.1% of total) may represent cells that
have completed camptothecin-induced apoptosis before
others, because less than 5% of cells were in this state
before the addition of camptothecin. Rare caspase+/annexin
V cells (4.9%) were also found.
To examine whether active Cy–annexin V might serve as
an NIRF imaging agent, we imaged a mouse with chemo-
sensitive LLCs and chemoresistant CR-LLCs implanted in
the mammary fat pads after CPA treatment (Figure 3, A–C).
In preliminary experiments, it was shown that tumor NIRF
reached a stable peak between 75 and 1200 minutes after
injection of active Cy–annexin V. An imaging time of 90
minutes postinjection was therefore chosen as optimal. Sup-
porting this time for optical imaging are pharmacokinetic
studies with Tc annexin V, which indicate that it has a blood
half-life of less than 30minutes [29]. Figure 3 shows the white
light image (A ), the raw NIRF image (B ), and a colored NIRF
image (C ) of the mouse. The chemosensitive LLC tumor had
a visibly higher signal intensity than the chemoresistant CR-
LLC tumor, a result that was confirmed with region of interest
(ROI) measurements of tumor signal intensity and with addi-
tional animals (see Figure 4). Also shown is a mouse
implanted with chemosensitive LLC and chemoresistant
CR-LLC tumors, treated with CPA and injected with inactive
Cy–annexin V (Figure 3D). In this case, tumor NIRF was
lower and only equal to background, a result again confirmed
with additional animals (see below). We conclude that the
Figure 1. Competition assay for the ability of Cy5.5–annexin V conjugates to bind PS on the surface of camptothecin-treated Jurkat T cells. Displacement of FITC–
annexin V (FACSFL1 channel)with a 10-fold excessofCy5.5–annexinV preparations labeledwith increasingnumbers ofCy5.5 dyespermole of protein. Asn decreases
(back to front), Cy5.5–annexin Vs become more effective inhibitors of FITC–annexin V binding.
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tumor NIRF signal obtained with active Cy–annexin V
depended on PS binding, rather than on some nonspecific
mechanism of accumulation, based on the lack of signal
obtained with inactive Cy–annexin V.
A TUNEL stain for the apoptotic cells present in LLC and
CR-LLC tumors is shown in Figure 3, E and F. Using addi-
tional sections, we determined that the apoptotic index after
CPA treatment was 89.1F 9.3 and 36.7F 5.1 for the LLC
and CR-LLC tumors, respectively. Hence, the apoptotic
index was dependent on the chemosensitivity of the tumor.
NIRF signal intensity data were quantified by taking ROI
signal intensity measurements for chemosensitive LLC and
chemoresistant CR-LLC tumors and for areas adjacent to the
tumor, after an injection of active Cy–annexin V. Results are
summarized in Figure 4. After treatment with CPA, the
chemosensitive LLC had a TAR of 2.56F 0.29 compared to
1.89F 0.19 for CR-LLC,whichwere different at a significance
of P= .002 using a paired Student’s t-test. Hence, after CPA
treatment, TAR was a function of tumor chemosensitivity.
Also of note is the fact that CPA treatment significantly
increased the TAR of both the LLC and CR-LLC tumors,
and statistical significance of this increase was higher for the
LLC than the CR-LLC tumor. CPA treatment increased the
TAR of the chemosensitive LLC tumor (1.22F 0.34 to
2.56F 0.29, P = .001, unpaired Student’s t-test), whereas
the chemoresistant CR-LLC tumors had a more modest
TAR increase (1.43F 0.53 to 1.89F 0.19, P= .183, unpaired
Student’s t-test). When inactive Cy–annexin V was injected
Figure 2. Labeling of untreated and camptothecin-treated Jurkat T cells with active Cy5.5–annexin V. (A) Untreated cells incubated with active Cy–annexin V and
FITC–annexin V. The FL1 channel is for fluorescein whereas FL4 is for Cy5.5. Unlabeled cells are in the left quadrant (91.8%), whereas cells labeled with both
annexin Vs are in the upper right quadrant (7.2%). (B) Camptothecin-treated cells incubated with active Cy–annexin V and FITC–annexin V. Double-labeled cells
are in the upper right quadrant (59.1%), with unlabeled cells in the lower left quadrant (36.7%). (C) Fluorescence micrographs of camptothecin-treated cells stained
with active Cy–annexin V and the caspase probe FITC-VAD-FMK. A membrane-bound NIRF signal from active Cy–annexin V and a cytoplasmic green
fluorescence from FITC-VAD-FMK are seen.
190 Imaging Chemotherapy Response with Optical Imaging Schellenberger et al.
Neoplasia . Vol. 5, No. 3, 2003
into LLC and CR-LLC tumor-bearing animals, with or without
CPA treatment, tumor NIRF/backgroundNIRF values ranged
from 0.99 to 1.17 and the magnitude of nontumor signal
intensity (background) was similar using active Cy–annexin
V or inactive Cy–annexin V.
Discussion
Active Cy–annexin V binds to LLC xenografts after treatment
with CPA, yielding an NIRF signal that can be quantified from
outside a nude mouse using a surface reflectance type of
instrumentation. The magnitude of tumor NIRF depended on
the history of CPA treatment and the sensitivity of the tumor to
CPA. The tumor NIRF obtained resulted from the binding of
active Cy–annexin V to PS, a conclusion based on the lack of
signal obtained with inactive Cy–annexin V. Synthesis of an
active and an inactive Cy–annexin V was accomplished by
altering the extent of modification of the protein with the N-
hydroxysuccinimide ester of Cy5.5 (activeCy–annexin V, 1.1
Cy5.5 dyes/annexin V versus inactive Cy–annexin V, 2.4
dyes/annexin V). Active and inactive forms of Cy–annexin V
have identical amino acid sequences and compositions, and
similar molecular weights. The molecular masses of annexin
V and Cy5.5 are 36 and 0.900 kDa, respectively, so active
Cy–annexin V [totalmass = 1.1(0.900) + 36 kDa] and inactive
Cy–annexin V [total mass = 2.4(0.90) + 36 kDa] differ by only
1.35 kDa. Because of the many similarities between the two
forms of annexin V, inactive Cy–annexin V is an ideal probe
for demonstrating that the tumor NIRF obtained with active
Cy–annexin V depends on PS binding.
The accumulation of radioactive annexin V in tissues, as
determined by imaging, has often been related to the extent
of tissue apoptosis [1,2]. The TAR for the CPA-treated
chemosensitive LLC tumor (2.56F 0.29) was associated with
an apoptotic index of 89F 9.1, whereas the TAR for the
chemoresistant CR-LLC tumor (1.89F 0.19) was associated
with a lower apoptotic index of 36.7F 5.1. However, the value
of active Cy–annexin V for imaging the effectiveness of a
chemotherapeutic regime may not depend on whether the
NIRF signal obtained originates only from its binding exclu-
sively to apoptotic cells. First, PS exposure and annexin V
binding are characteristics of necrotic as well as apoptotic
cells [4,27]. When imaging the effectiveness of chemother-
apy, it maybe preferable to image cells that have died from
either apoptotic or nonapoptotic mechanisms of cell death.
Second, apoptotic cells are rapidly phagocytized in a process
where PS recognition may play an important role
[6,10,17,22]. This leads to the possibility that an NIRF signal
may arise from phagocytic cells, which do not express
extracellular-facing PS but have consumed NIRF apoptotic
cells. Finally, PS exposure maybe reversible and precede a
commitment to apoptosis [9].
Figure 3. In vivo imaging of LLC implanted in the mammary fat pads of nude mice. LLC indicates CPA-sensitive and CR-LLC indicates CPA-resistant tumor. (A)
White light image 90 minutes after injection of active annexin V. (B) Raw NIRF image of (A). (C) Color-coded map of NIRF intensity superimposed on the white light
image. (D) Raw image of tumors after CPA treatment and injection of inactive Cy annexin V. (E) TUNEL stain of the LLC tumor. (F) TUNEL stain of the CR-LLC
tumor.
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The use of active Cy–annexin V and the simple reflec-
tance NIRF imaging equipment we employed [13,28] pro-
vides a convenient method of imaging tumor PS exposure,
which served as marker of tumor sensitivity to CPA treat-
ment. Future studies based on this method will determine
whether similar observations will apply with other tumor
models. With humans, surface reflectance fluorescence
imaging methods would seem to be impractical because of
the longer distances light must traverse. However, the rapid
development of fluorescence-mediated tomographic imag-
ing methods now permits the quantitation of the NIRF signals
emanating from sources deep within small animals [18–20]
and may someday be used to image NIRF with humans. The
acceptability of annexin V for use in human studies and the
rapid development of NIRF-based imaging instrumentation
may make the optical method for imaging of tumor PS, using
an NIRF conjugate of annexin V, a clinical possibility.
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